Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia

NCT07696481 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Acute Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Myeloid Leukemia (AML)

Interventions

BIOLOGICAL: PID23 Injection

Sponsor

Zhujiang Hospital

Collaborators

[object Object]